Medications Affecting the Insulin-Like Growth Factor 1/Growth Hormone Axis, Including Teprotumumab, Somatostatin Analogs, and Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies, Are Associated With Elevated Reporting Odds of Alopecia in Women: A Pharmacovigilance Study

    April 2023 in “ Journal of The American Academy of Dermatology ”
    Patrick Jedlowski, Mahdieh F. Jedlowski, Mohammad Reza Fazel
    Studysummary This study investigated the association between hair loss and medications affecting the GH/IGF-1 pathway, using the FDA Adverse Event Reporting System to analyze reporting odds ratios of alopecia.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on jaad.org →
    Discuss this study in the Community →

    Research cited in this study 3

    1. Growth Hormone and the Human Hair Follicle International journal of molecular sciences · 2021
    2. Role of Insulin-Like Growth Factor-1 Receptor in Female Androgenetic Alopecia Menoufia Medical Journal · 2020
    3. Scalp Hair Loss After Transsphenoidal Adenomectomy in Patients With Acromegaly Clinical Endocrinology · 2012